Sponsored Symposia

Sponsored Symposia

Add Sponsored Symposia to your schedule and connect with industry supporters to learn about developments and technologies in the field of cancer immunotherapy.

Sponsored Symposia content and views expressed therein are those of the sponsoring organization and not of SITC.

Friday, Nov. 3, 2023

Champalimaud Foundation

Friday, Nov. 3, 2023  | 12:15-1:15 p.m.  |  Room 11AB

Synthetic biology - cell therapy for patients with solid cancer

We are embarking on an unprecedented era of therapeutic development enabled by live cell engineering. Genetic engineering of cells goes beyond a simplistic ´´hit-and-kill´´ approach using synthetic biology to enable smart decisions that allows transgenic cells to react in response to systemic cues and to the tumor-microenvironment with the aim to amplify anti-tumor directed immune responses. GMP-production, safety, target-specificity, and longevity of an autologous immune-cell graft targeting transformed cells are key unmet needs in designing cell therapies for patients with solid cancer. Innovative solutions include the possibility to rewire decision making of transgenic cells in regard to quality and strength of contextual immune effectorfunctions as well as epigenetic programming. Preclinical and clinical implementation surpasses the individual public, non-profit or industrial entities and calls for cross-fertilizing cooperation. The opportunity to develop a pre-competitive consortium of stakeholders can provide a nurturing environment to discuss challenges, outline solutions, and foster collaborations in order to achieve the ultimate goal of significantly improving the survival of patients with cancer.

Introduction: Dr. Markus Maeurer, Champalimaud Foundation, Lisbon, Portugal; Dr. Franco Marincola, Sonata, Boston, USA
Keynotes: Dr. Qi Cai, Director of Cell Biology, Kite Pharma, CA, USA; Dr. Jason Bock, CEO, CTMC, TX, USA
Perspectives: Dr. George Coukos, Ludwig Institute for Cancer Research; Dr. Sergio Quezada, UCL London

Lunaphore Technologies

Friday, Nov. 3, 2023  | 12:15-1:15 p.m. | Room 15AB

Using hyperplex immunoflourescence to characterize the immune response to isabr in head and neck cancer

Collaborators from the Earle A. Chiles Research Institute (EACRI) at Providence Health and Lunaphore report on a project to develop a hyperplex immunofluorescence panel on the COMETTM platform for the comprehensive characterization of the tumor microenvironment in response to combined immunotherapy and stereotactic ablative radiation therapy (iSABR) neoadjuvant treatment of head and neck squamous cell carcinoma (HNSCC). The team will discuss strategies for rapid hyperplex seqIFTM panel development and optimization as well as methodologies for high-throughput data analytics. The team will show results of tumor microenvironment remodeling in a spatiotemporal context, for neoadjuvant iSABR in HNSCC.

Speakers:Dr. Brian Piening, PhD - Providence Cancer Institute – Earle A. Chiles Research InstitutePortland, Oregon, USADr. Rom Leidner, MD Providence Cancer Institute – Earle A. Chiles Research InstitutePortland, Oregon, USA


Friday, Nov. 3, 2023  | 12:15-1:15 p.m.  |  Room 17AB

A first-line Treatment Option for Certain Patients With Advanced Esophageal Cancer or gej cancer

Learning Objectives:
- Provide an overview of esophageal cancer and gastroesophageal junction (GEJ) cancer
- Review hypothetical patient cases of advanced esophageal cancer
- Present the clinical data for a a 1L treatment option in certain patients with advanced esophageal or GEJ cancer

NanoString Technologies

Friday, Nov. 3, 2023  | 12:15-1:15 p.m.  |  Room 16AB

Revolutionizing Immuno-oncology with Spatial Biology

NanoString’s Spatial Biology solutions provide unprecedented opportunities to understand how cells organize and regulate across the tissue landscape to drive disease progression and response to anti-cancer therapies. Join us to learn about the GeoMx IO Proteome Atlas (IPA), the most comprehensive human spatial proteomics assay enabling spatial profiling of 500+ immuno-oncology (IO) relevant targets from FFPE tissue sections; containing nearly all IHC-compatible antibodies from Abcam’s IO catalog.  Hear from Dr. David Ting, MGH, and his use of spatial proteogenomics, single slide utilizing both Whole Transcriptome Atlas (WTA) and IPA for highest plex on randomized pancreatic cancer immunotherapy clinical trial samples.   Learn how spatial technologies can power your immunotherapy research, improve your understanding of cancer development, progression, and microenvironment interactions, enhance your biomarker discovery, and streamline your therapeutic development.

Speakers (NSTG & external KOL):  Vik Devgan, Joe Beechem, David Ting, MD, Massachusetts General Hospital


Friday, Nov. 3, 2023  | 12:15-1:15 p.m.  |  Exh. Hall Presentation Stage

multimodal data integration to advance personalized medicine in lung cancer: an overview of dliv study

Over the last 20 years, targeted compounds have been proven effective for non-small cell lung cancer (NSCLC patients), but recent scientific breakthroughs have made immunotherapies a new pillar of cancer care. These recent advances, coupled with the avalanche of health data, have made it hard for medical professionals to identify the patient sub-groups that will benefit the most from immunotherapy, alone or in combination with chemotherapy, without experiencing significant side effects. By using deep learning and artificial intelligence frameworks to integrate multiple biomarkers, SOPHiA GENETICS’ DEEP-Lung-IV study (NCT04994795) aims to improve the accuracy of prognosis and first-line treatment planning. Join us to discover how this study is helping medical researchers integrate different health data modalities in a meaningful way, breaking through the data silos and expanding the power and reach of collective intelligence in healthcare.


Friday, Nov. 3, 2023  | 5:10-6:40 p.m.  |  Exh. Hall Presentation Stage

A Promising Biomarker for Tumor Immunogenicity: Unveiling the Potential of Immunoscore® IC (CD8/PDL1) Assay

The field of immunotherapy has witnessed remarkable advancements in recent years, revolutionizing the way we combat cancer. One of the key factors driving these breakthroughs is the identification and utilization of biomarkers that enable clinicians to tailor treatments for individual patients. This symposium will showcase the Immunoscore® Immune Checkpoint (CD8/PDL1) assay. Experts will provide an in-depth review of the assay’s analytical performance, clinical relevance, and efficacy, with a focus on metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).

Join us to engage in a dynamic discussion with our experts, addressing key questions, potential challenges, and future directions in harnessing Immunoscore® IC for precision immunotherapy.

Saturday, Nov. 4, 2023


Saturday, Nov. 4, 2023  | 12:15-1:15 p.m.  |  Room 15AB

Evolving Biomarker Landscape in Gastric and Gastroesophageal Junction Adenocarcinomas

GE HealthCare

Saturday, Nov. 4, 2023  | 12:15-1:15 p.m.  |  Room 16AB

Predicting Efficacy and Toxicities Prior to Immune Checkpoint Inhibitor Treatment, using patient electronic health records

Responses to immune checkpoint inhibitor treatments in oncology are still heterogeneous and not fully predictable for an individual patient. Some patients develop significant and possibly life-threatening immune-related toxicities. In this symposium, GE HealthCare (GEHC) and Vanderbilt University Medical Center (VUMC) report on the progress of their co-developed predictive models, using baseline routine patient data, to predict efficacy of ICI treatment and the likelihood of some of the most common toxicities.


Saturday, Nov. 4, 2023  | 12:15-1:15 p.m.  |  Room 17AB

Advancements in Biomarker-driven Care for Gynecological Malignancies

Professor Melissa A. Geller, MD, MS, FACOG (Professor of Gynecologic Oncology, University of Minnesota Medical School) will review how understanding has evolved around molecular subtypes in these diseases, how this information currently guides treatment selection and influences patient outcomes, and which clinical biomarkers will inform the future standard of care. GSK is proud to partner with experts in the field to bring educational resources to support you and your patients.


Saturday, Nov. 4, 2023  | 12:15-1:15 p.m.  |  Exh. Hall Presentation Stage

Spatial Biology and beyond: Decoding of immunological landscapes to develop novel therapeutic approaches

In this symposium you will learn how the combination of state of the art imaging techniques can decode immunological landscapes. Be amazed by newly designed workflows, combining imaging mass spectrometry, bioinformatics and spatial biology solutions to understand the mechanisms of leukocyte migration and function.